Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $2.52, $0.04 worse than the analyst estimate of $2.56. Revenue for the quarter came in at $340.9 million versus the consensus estimate of $348.15 million.

Jazz Pharmaceuticals sees FY2015 EPS of $9.45-$9.60, versus the consensus of $9.67. Jazz Pharmaceuticals sees FY2015 revenue of $1.32-1.34 million, versus the consensus of $1.36 million.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.

Earnings Guidance Hot Earnings Hot Guidance

Jazz Pharmaceuticals (JAZZ) PT Cut to $170 at Canaccord GenuityNovember 10, 2015 10:20 AM Delays at the central pharmacy Negatively Hit Jazz Pharmaceuticals (JAZZ); Piper Jaffray Cuts Price Target to $186 November 10, 2015 9:51 AM Jazz Pharmaceuticals (JAZZ) Reports Topline Miss Related to Delays in Xyrem Refills; Leerink Partners Cuts Price Target to $187 November 10, 2015 8:42 AM Mizuho Securities Downgrades Jazz Pharmaceuticals (JAZZ) to NeutralNovember 10, 2015 6:31 AM Jazz Pharmaceuticals Announces Third Quarter 2015 Financial ResultsNovember 9, 2015 4:06 PM